Abstract
Introduction: In colorectal cancer (CRC), the prognostic significance of Adenomatous polyposis coli (APC) mutations remains controversial. We aimed to investigate the effect of APC mutations on the prognosis of patients with CRC and to elucidate the clinicopathological features associated with these mutations. Methods: Formalin-fixed, paraffin-embedded CRC specimens were tested for APC mutations using targeted next-generation sequencing, mismatch repair (MMR) deficiency was evaluated using immunohistochemical staining. Clinicopathological features were obtained from medical records and through a review of hematoxylin and eosin slides. Results:APC mutations and MMR deficiencies were detected in 72.8% and 8.9% of the patients with CRC, respectively. APC mutations were significantly correlated with male sex (p = 0.046) and left colon cancer (p < 0.001). They were inversely correlated with age (p = 0.020), serum 19-9 elevation (p = 0.047), distant metastasis (p = 0.005) and MMR deficiency (p < 0.001). In univariate analysis, APC mutations correlated with longer overall survival in patients with CRC. Conclusions:APC mutations are associated with favorable prognostic factors and longer overall survival. Further investigation is needed to understand the mechanisms of association between APC mutations to favorable cancer prognosis and their correlation MMR protein expression.
Journal Section:
Oncology and Informatics
References
1.
Sung
H
, Ferlay
J
, Siegel
R
, Laversanne
M
, Soerjomataram
I
, Jemal
A
, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2021
;71
(3
):209
–49
. 2.
Katsaounou
K
, Nicolaou
E
, Vogazianos
P
, Brown
C
, Stavrou
M
, Teloni
S
, et al. Colon cancer: from epidemiology to prevention
. Metabolites
. 2022
;12
(6
):499
–525
. 3.
Buccafusca
G
, Proserpio
I
, Tralongo
AC
, Rametta Giuliano
S
, Tralongo
P
. Early colorectal cancer: diagnosis, treatment and survivorship care
. Crit Rev Oncol Hematol
. 2019
;136
:20
–30
. 4.
Zhan
T
, Rindtorff
N
, Boutros
M
. Wnt signaling in cancer
. Oncogene
. 2017
;36
(11
):1461
–73
. 5.
Brocardo
M
, Henderson
BR
. APC shuttling to the membrane, nucleus and beyond
. Trends Cel Biol
. 2008
;18
(12
):587
–96
. 6.
Jaiswal
AS
, Narayan
S
. A novel function of adenomatous polyposis coli (APC) in regulating DNA repair
. Cancer Lett
. 2008
;271
(2
):272
–80
. 7.
Christie
M
, Jorissen
R
, Mouradov
D
, Sakthianandeswaren
A
, Li
S
, Day
F
, et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis
. Oncogene
. 2013
;32
(39
):4675
–82
. 8.
Schell
MJ
, Yang
M
, Teer
JK
, Lo
FY
, Madan
A
, Coppola
D
, et al. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
. Nat Commun
. 2016
;7
:11743
–54
. 9.
Wang
C
, Ouyang
C
, Cho
M
, Ji
J
, Sandhu
J
, Goel
A
, et al. Wild‐type APC is associated with poor survival in metastatic microsatellite stable colorectal cancer
. Oncologist
. 2021
;26
(3
):208
–14
. 10.
Innocenti
F
, Rashid
N
, Wancen
M
, Ou
F-S
, Qu
X
, Denning
S
, et al. Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): novel mutated genes and their effect on response to therapy (Alliance)
. Ann Oncol
. 2019
;30
(5
):198
–9
. 11.
Conlin
A
, Smith
G
, Carey
FA
, Wolf
CR
, Steele
RJ
. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
. Gut
. 2005
;54
(9
):1283
–6
. 12.
Birgisson
H
, Edlund
K
, Wallin
U
, Påhlman
L
, Kultima
HG
, Mayrhofer
M
, et al. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer
. BMC cancer
. 2015
;15
:125
–35
. 13.
Le
DT
, Uram
JN
, Wang
H
, Bartlett
BR
, Kemberling
H
, Eyring
AD
, et al. PD-1 blockade in tumors with mismatch-repair deficiency
. N Engl J Med
. 2015
;372
(26
):2509
–20
. 14.
Wang
J
, Li
R
, He
Y
, Yi
Y
, Wu
H
, Liang
Z
. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas
. Mod Pathol
. 2020
;33
(12
):2591
–601
. 15.
Cancer Genome Atlas Network
. Comprehensive molecular characterization of human colon and rectal cancer
. Nature
. 2012
;487
(7407
):330
–7
. 16.
Giannakis
M
, Mu
XJ
, Shukla
SA
, Qian
ZR
, Cohen
O
, Nishihara
R
, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma
. Cell Rep
. 2016
;15
(4
):857
–65
. 17.
Korinek
V
, Barker
N
, Morin
PJ
, Van Wichen
D
, De Weger
R
, Kinzler
KW
, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC−/− colon carcinoma
. Science
. 1997
;275
(5307
):1784
–7
. 18.
Jass
JR
, Young
J
, Leggett
BA
. Evolution of colorectal cancer: change of pace and change of direction
. J Gastroenterol Hepatol
. 2002
;17
(1
):17
–26
. 19.
Aghabozorgi
AS
, Bahreyni
A
, Soleimani
A
, Bahrami
A
, Khazaei
M
, Ferns
GA
, et al. Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives
. Biochimie
. 2019
;157
:64
–71
. 20.
Zhang
L
, Shay
JW
. Multiple roles of APC and its therapeutic implications in colorectal cancer
. J Natl Cancer Inst
. 2017
;109
(8
):332
–41
. 21.
Fodde
R
, Kuipers
J
, Rosenberg
C
, Smits
R
, Kielman
M
, Gaspar
C
, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability
. Nat Cel Biol
. 2001
;3
(4
):433
–8
. 22.
Ding
Z
, Jiang
T
, Piao
Y
, Han
T
, Han
Y
, Xie
X
. Meta-analysis of the association between APC promoter methylation and colorectal cancer
. Onco Targets Ther
. 2015
;8
:211
–22
. 23.
Garg
M
, Lincz
L
, Adler
K
, Scorgie
F
, Ackland
S
, Sakoff
J
. Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis
. Br J Cancer
. 2012
;107
(9
):1525
–33
. 24.
González-Perera
I
, Gutiérrez-Nicolás
F
, Nazco-Casariego
GJ
, Ramos-Díaz
R
, Hernández-San Gil
R
, Pérez-Pérez
JA
, et al. 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A> G (rs67376798)
. J Oncol Pharm Pract
. 2017
;23
(5
):396
–8
. 25.
Burger
JA
, Tedeschi
A
, Barr
PM
, Robak
T
, Owen
C
, Ghia
P
, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
. N Engl J Med
. 2015
;373
(25
):2425
–37
. 26.
Spranger
S
, Bao
R
, Gajewski
TF
. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
. Nature
. 2015
;523
(7559
):231
–5
. 27.
Hankey
W
, Frankel
WL
, Groden
J
. Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting
. Cancer Metastasis Rev
. 2018
;37
(1
):159
–72
. 28.
Flanagan
DJ
, Vincan
E
, Phesse
TJ
. Wnt signaling in cancer: not a binary ON: OFF switch
. Cancer Res
. 2019
;79
(23
):5901
–6
. 29.
Sekine
S
, Mori
T
, Ogawa
R
, Tanaka
M
, Yoshida
H
, Taniguchi
H
, et al. Mismatch repair deficiency commonly precedes adenoma formation in Lynch Syndrome-Associated colorectal tumorigenesis
. Mod Pathol
. 2017
;30
(8
):1144
–51
. 30.
Grothey
A
. Pembrolizumab in MSI-H-dMMR advanced colorectal cancer–a new standard of care
. N Engl J Med
. 2020
;383
(23
):2283
–5
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
